Indoxyl Sulfate Predicts Cardiovascular Disease and Renal Function Deterioration in Advanced Chronic Kidney Disease

2012 ◽  
Vol 43 (6) ◽  
pp. 451-456 ◽  
Author(s):  
Cheng-Jui Lin ◽  
Hsuan-Liang Liu ◽  
Chi-Feng Pan ◽  
Chih-Kuang Chuang ◽  
Thanasekaran Jayakumar ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Indoxyl Sulfate ◽  
Advanced Chronic Kidney Disease ◽  
Renal Function Deterioration

scholarly journals Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation by regulation of β-catenin and YAP pathways

2021 ◽  
Author(s):  
Ying Li ◽  
Jing Yan ◽  
Minjia Wang ◽  
Jing Lv ◽  
Fei Yan ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Inflammatory Response ◽  
Macrophage Polarization ◽  
Indoxyl Sulfate ◽  
Uremic Toxin ◽  
Lps Challenge ◽  
Hla Dr ◽  
M1 Macrophage

AbstractEvidence has been shown that indoxyl sulfate (IS) could impair kidney and cardiac functions. Moreover, macrophage polarization played important roles in chronic kidney disease and cardiovascular disease. IS acts as a nephron-vascular toxin, whereas its effect on macrophage polarization during inflammation is still not fully elucidated. In this study, we aimed to investigate the effect of IS on macrophage polarization during lipopolysaccharide (LPS) challenge. THP-1 monocytes were incubated with phorbol 12-myristate-13-acetate (PMA) to differentiate into macrophages, and then incubated with LPS and IS for 24 h. ELISA was used to detect the levels of TNFα, IL-6, IL-1β in THP-1-derived macrophages. Western blot assay was used to detect the levels of arginase1 and iNOS in THP-1-derived macrophages. Percentages of HLA-DR-positive cells (M1 macrophages) and CD206-positive cells (M2 macrophages) were detected by flow cytometry. IS markedly increased the production of the pro-inflammatory factors TNFα, IL-6, IL-1β in LPS-stimulated THP-1-derived macrophages. In addition, IS induced M1 macrophage polarization in response to LPS, as evidenced by the increased expression of iNOS and the increased proportion of HLA-DR+ macrophages. Moreover, IS downregulated the level of β-catenin, and upregulated the level of YAP in LPS-stimulated macrophages. Activating β-catenin signaling or inhibiting YAP signaling suppressed the IS-induced inflammatory response in LPS-stimulated macrophages by inhibiting M1 polarization. IS induced M1 macrophage polarization in LPS-stimulated macrophages via inhibiting β-catenin and activating YAP signaling. In addition, this study provided evidences that activation of β-catenin or inhibition of YAP could alleviate IS-induced inflammatory response in LPS-stimulated macrophages. This finding may contribute to the understanding of immune dysfunction observed in chronic kidney disease and cardiovascular disease.

scholarly journals Changes in renal function after discontinuation of vitamin D analogues in advanced chronic kidney disease

2018 ◽  
Vol 38 (2) ◽  
pp. 179-189
Author(s):  
Francisco Caravaca ◽  
Fernando Caravaca-Fontán ◽  
Lilia Azevedo ◽  
Enrique Luna
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Renal Function ◽  
Kidney Disease ◽  
Advanced Chronic Kidney Disease ◽  
Vitamin D Analogues

Kidney disease

2019 ◽  
pp. 317-342
Author(s):  
Debasish Banerjee ◽  
Robin Ramphul ◽  
David Goldsmith
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Renal Function ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Cardiovascular Events ◽  
Evidence Based ◽  
Altered Physiology ◽  
European Society Of Cardiology ◽  
Drug Handling

The cardiovascular disease profile in patients with chronic kidney disease, and liver disease and during pregnancy is different from that in the general population. Due to altered physiology in these conditions, drug handling is different. Hence, drug therapies in these conditions are described separately in this section. Cardiovascular disease is the commonest cause of morbidity and mortality in patients with chronic kidney disease. Yet drug therapy is often withheld or used in inappropriate doses. The kidneys have a major role in the pharmacokinetics of numerous drugs, and hence the renal function determines the dose and effect of these drugs. This chapter describes common cardiovascular events in chronic kidney disease patients and appropriate drug therapy. Evidence-based guidance is provided when appropriate, and the dose adjustments are as known, when available, in accordance to the current European Society of Cardiology guidelines.

Heart rate variability as a predictor of rapid renal function deterioration in chronic kidney disease patients

Nephrology ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 806-813 ◽  
Author(s):  
Yu‐Hsiang Chou ◽  
Wei‐Lieh Huang ◽  
Chin‐Hao Chang ◽  
Cheryl C. H. Yang ◽  
Terry B. J. Kuo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Renal Function ◽  
Kidney Disease ◽  
Renal Function Deterioration
Sign in / Sign up

Export Citation Format

Share Document